# Tirzepatide Philippines: SURMOUNT Trials, Side Effects

Source: https://www.philippinespeptides.com/peptides/tirzepatide
Updated: 2026-09-24

> Tirzepatide, the active ingredient in Mounjaro and Zepbound: how the dual GIP and GLP-1 agonist works, SURMOUNT trial findings, side effects and PH status.

On this page

- [Buying Tirzepatide in the Philippines](#buying-tirzepatide-in-the-philippines)

- [What is Tirzepatide](#what)

- [How it works](#how)

- [Tirzepatide in the Philippines](#ph-context)

- [Benefits studied](#benefits)

- [Side effects reported](#side-effects)

- [What the trials found](#trials)

- [Regulatory status](#regulatory)

- [Who should not use Tirzepatide](#contraindications)

- [FAQ](#faq)

- [Where to get Tirzepatide in the Philippines](#sourcing)

- [Primary sources](#sources)

Weight loss · Compound

# Tirzepatide

Philippines Peptides editorial desk Updated 24 September 2026 Trial data checked 23 September 2026 15 min read 5 sources

**Class**

- Peptide dual incretin receptor agonist

**Targets**

- GIP and GLP-1 receptors

**Evidence level**

- Approved medicine

**FDA Philippines**

- Registered Registered only as the branded prescription medicine Mounjaro (12 certificates)

**US FDA**

- Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound)

**Randomised human trials**

- 5

**Checked**

- 23 September 2026

**Tirzepatide in the Philippines: pharmacy prices and availability.** This page covers the molecule itself: mechanism, trial findings, side effects and regulatory status. For Philippine Mounjaro availability, Zepbound status and pharmacy prices, read the 2026 guide. [Read the Tirzepatide Philippines 2026 guide →](https://www.philippinespeptides.com/guides/tirzepatide-philippines-2026)

**Body weight fell on the 15 mg arm in SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, against 3.1% on placebo**

- 20.9%

**Completed trials with a reported result in the Research Desk dataset**

- 5

The strongest evidence found for Tirzepatide comes from phase 3 human trials, and every finding below carries its evidence level.

Availability in the Philippines

## Buying Tirzepatide in the Philippines

**Availability**

- Mounjaro KwikPen listed by Watsons, Southstar Drug and Rose Pharmacy in every strength. No Philippine registration identified for Zepbound.

**Price range**

- ₱11,650 to ₱29,900 per Mounjaro KwikPen (Rx) at Watsons, checked 23 September 2026

**Sourcing channel**

- Prescription from a licensed Philippine physician, filled at a registered pharmacy

Tirzepatide as a prescription medicine in the Philippines

Branded Mounjaro is listed by Philippine drugstore chains against a prescription, and prescribing belongs with a licensed Philippine physician. A research-grade vial of tirzepatide is not a registered medicine and is not a substitute for a prescribed pen.

## What is Tirzepatide

Tirzepatide is a single peptide that activates two receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. It was developed by Eli Lilly and is the active ingredient in Mounjaro and Zepbound. The US FDA approved Mounjaro on 13 May 2022 for glycemic control in type 2 diabetes, and Zepbound on 8 November 2023 for weight reduction in obesity or overweight with a comorbidity and for moderate to severe obstructive sleep apnea in adults with obesity. Each approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.

The strongest evidence for tirzepatide is phase 3 human. The SURMOUNT-1 to SURMOUNT-4 trials studied it in obesity and overweight, obesity with type 2 diabetes, and maintenance of weight reduction, and the phase 3b SURMOUNT-5 trial compared it head to head with [semaglutide](https://www.philippinespeptides.com/peptides/semaglutide). The figures from those trials, and the adverse events reported in them, are set out in the sections below.

Tirzepatide is a prescription medicine, and prescribing belongs with a licensed Philippine physician. The [weight loss hub](https://www.philippinespeptides.com/weightloss) lists the other compounds this site covers.

## How it works

GLP-1 receptor: tirzepatide activates the GLP-1 receptor, the same receptor semaglutide targets. The Mounjaro prescribing information describes the resulting effects in people as glucose-dependent insulin secretion, lower glucagon levels, delayed gastric emptying and reduced food intake.

GIP receptor: tirzepatide also activates the GIP receptor. In the animal studies reported in the 2018 discovery paper (Coskun et al., Mol Metab), the dual agonist reduced body weight more than a selective GLP-1 receptor agonist.

Human comparisons: in people, the comparison with a GLP-1-only agonist comes from head-to-head trials against semaglutide: SURPASS-2 in type 2 diabetes (N Engl J Med 2021) and SURMOUNT-5 in obesity, whose result is in the Benefits studied section.

## Tirzepatide in the Philippines

Tirzepatide is sold in the Philippines as Mounjaro, a once-weekly KwikPen registered with FDA Philippines as a prescription drug. On 23 September 2026 Watsons, Southstar Drug and Rose Pharmacy listed every strength online; current prices by pharmacy are on the Mounjaro price page. No Philippine registration has been identified for Zepbound, the brand Lilly uses for obesity in the United States.

FDA Philippines lists 12 certificates of product registration for Mounjaro, covering the KwikPen and single-dose vial presentations, each a prescription drug. FDA Advisory No. 2026-0065 added tirzepatide 2.5 mg to 15 mg per 0.6 mL solution for injection to the list of VAT-exempt health products for diabetes under the CREATE Act.

The same regulator has warned against tirzepatide sold outside that system 3 times: FDA Advisory No. 2026-1019, 4 September 2026, FDA Advisory No. 2026-1020, 4 September 2026, FDA Advisory No. 2026-0814, 30 July 2026. Each advisory names a product with no Certificate of Product Registration, and 2 of them describe a vial sold with bacteriostatic water. The advisories are listed in full on the regulation hub.

In research terms the evidence dataset rates tirzepatide phase 3 human, the highest level it uses. Completed phase 3 trials SURMOUNT-1 to SURMOUNT-4 and the phase 3b head-to-head SURMOUNT-5 against semaglutide. Those trials, and every approval, concern Lilly's medicine. The US FDA note in the regulatory dataset says an approval covers the named branded medicine for its labelled use only, never a research-grade vial of the same substance.

A research-grade vial of tirzepatide is a different category of product: not a registered medicine, not dispensed by a pharmacist, and not a substitute for a prescribed pen. Prescribing belongs with a licensed Philippine physician.

## Benefits studied

- Body-weight reduction: Phase 3 human SURMOUNT-1, a phase 3 trial of 2,539 adults with obesity or overweight and no diabetes, recorded an average 20.9% fall in body weight on the 15 mg arm at 72 weeks, against 3.1% on placebo. [Source: Jastreboff AM et al. N Engl J Med 2022;387:205-216](https://doi.org/10.1056/NEJMoa2206038)

- Body-weight reduction with type 2 diabetes: Phase 3 human SURMOUNT-2 (phase 3, 938 adults with type 2 diabetes and a BMI of 27 or more) found an average 14.7% weight loss on 15 mg over 72 weeks, against 3.2% on placebo. [Source: Garvey WT et al. Lancet 2023 (SURMOUNT-2)](https://doi.org/10.1016/s0140-6736(23)01200-x)

- Maintenance of weight reduction: Phase 3 human SURMOUNT-4, a phase 3 withdrawal trial of 670 people, found that those who stayed on tirzepatide after a 36-week lead-in lost a further 5.5% by week 88, while those moved to placebo regained 14.0%. [Source: Aronne LJ et al. JAMA 2024 (SURMOUNT-4)](https://doi.org/10.1001/jama.2023.24945)

- Body-weight reduction against semaglutide: Phase 3 human SURMOUNT-5, a phase 3b head-to-head trial of 751 adults with obesity and no type 2 diabetes, measured 20.2% average weight loss on tirzepatide against 13.7% on semaglutide over 72 weeks. [Source: Aronne LJ et al. N Engl J Med 2025 (SURMOUNT-5)](https://doi.org/10.1056/NEJMoa2416394)

## Side effects reported

**SURMOUNT-1**, a 72-week phase 3 trial of 2,539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, reported:

Adverse events in SURMOUNT-1, share of participants

| Adverse event | 5 mg | 10 mg | 15 mg | Placebo |
| --- | --- | --- | --- | --- |
| Discontinuation for adverse events | 4.3% | 7.1% | 6.2% | 2.6% |

[Source](https://doi.org/10.1056/NEJMoa2206038)

- Discontinuation for adverse events: 4.3%, 7.1% and 6.2% on the 5, 10 and 15 mg arms, against 2.6% on placebo.

**SURMOUNT-3**, a 72-week phase 3 trial of 579 adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention, reported:

Adverse events in SURMOUNT-3, share of participants

| Adverse event | Maximum tolerated dose (10 or 15 mg) | Placebo |
| --- | --- | --- |
| Discontinuation for adverse events | 10.5% | 2.1% |
| Nausea | 39.7% | 14% |
| Diarrhoea | 31% | 9.2% |
| Constipation | 23% | 6.8% |
| Vomiting | 18.1% | 1.4% |

[Source](https://doi.org/10.1038/s41591-023-02597-w)

- Discontinuation for adverse events: 10.5% on the Maximum tolerated dose (10 or 15 mg) arm, against 2.1% on placebo.

- Nausea: 39.7% on the Maximum tolerated dose (10 or 15 mg) arm, against 14% on placebo.

- Diarrhoea: 31% on the Maximum tolerated dose (10 or 15 mg) arm, against 9.2% on placebo.

- Constipation: 23% on the Maximum tolerated dose (10 or 15 mg) arm, against 6.8% on placebo.

- Vomiting: 18.1% on the Maximum tolerated dose (10 or 15 mg) arm, against 1.4% on placebo.

**SURMOUNT-4**, an 88-week phase 3 trial of 670 adults with BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes, reported:

Adverse events in SURMOUNT-4, share of participants

| Adverse event | Continued tirzepatide, weeks 36 to 88 | Switched to placebo |
| --- | --- | --- |
| Discontinuation for adverse events | 1.8% | 0.9% |
| Diarrhoea | 10.7% | 4.8% |
| Nausea | 8.1% | 2.7% |
| Vomiting | 5.7% | 1.2% |

[Source](https://doi.org/10.1001/jama.2023.24945)

- Discontinuation for adverse events: 1.8% on the Continued tirzepatide, weeks 36 to 88 arm, against 0.9% on switched to placebo.

- Diarrhoea: 10.7% on the Continued tirzepatide, weeks 36 to 88 arm, against 4.8% on switched to placebo.

- Nausea: 8.1% on the Continued tirzepatide, weeks 36 to 88 arm, against 2.7% on switched to placebo.

- Vomiting: 5.7% on the Continued tirzepatide, weeks 36 to 88 arm, against 1.2% on switched to placebo.

## What the trials found

In SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, body weight fell by 15%, 19.5% and 20.9% on the 5 mg, 10 mg and 15 mg arms, against 3.1% on placebo. [Source](https://doi.org/10.1056/NEJMoa2206038) · [Registry](https://clinicaltrials.gov/study/NCT04184622)

Completed trials of Tirzepatide with a reported result. Outcome: body weight

| Trial and population | n | Weeks | Change by arm | Comparator | Source |
| --- | --- | --- | --- | --- | --- |
| SURMOUNT-1 · Phase 3Adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes | 2,539 | 72 | 5 mg **−15%** 10 mg **−19.5%** 15 mg **−20.9%** | Placebo −3.1% | [Source](https://doi.org/10.1056/NEJMoa2206038) · [Registry](https://clinicaltrials.gov/study/NCT04184622) |
| SURMOUNT-2 · Phase 3Adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries | 938 | 72 | 10 mg **−12.8%** 15 mg **−14.7%** | Placebo −3.2% | [Source](https://doi.org/10.1016/s0140-6736(23)01200-x) · [Registry](https://clinicaltrials.gov/study/NCT04657003) |
| SURMOUNT-3 · Phase 3Adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention | 579 | 72 | Maximum tolerated dose (10 or 15 mg) **−18.4%** | Placebo 2.5% | [Source](https://doi.org/10.1038/s41591-023-02597-w) · [Registry](https://clinicaltrials.gov/study/NCT04657016) |
| SURMOUNT-4 · Phase 3Adults with BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes | 670 | 88 | Continued tirzepatide, weeks 36 to 88 **−5.5%** | Switched to placebo 14% | [Source](https://doi.org/10.1001/jama.2023.24945) · [Registry](https://clinicaltrials.gov/study/NCT04660643) |
| SURMOUNT-5 · Phase 3bAdults with obesity but without type 2 diabetes | 751 | 72 | Tirzepatide, maximum tolerated dose **−20.2%** | Semaglutide, maximum tolerated dose −13.7% | [Source](https://doi.org/10.1056/NEJMoa2416394) · [Registry](https://clinicaltrials.gov/study/NCT05822830) |

Body weight change on the highest-dose arm against the comparator, Tirzepatide trials

| Trial | Highest-dose arm | Comparator |
| --- | --- | --- |
| SURMOUNT-1 | 15 mg −20.9% | Placebo −3.1% |
| SURMOUNT-2 | 15 mg −14.7% | Placebo −3.2% |
| SURMOUNT-3 | Maximum tolerated dose (10 or 15 mg) −18.4% | Placebo 2.5% |
| SURMOUNT-4 | Continued tirzepatide, weeks 36 to 88 −5.5% | Switched to placebo 14% |
| SURMOUNT-5 | Tirzepatide, maximum tolerated dose −20.2% | Semaglutide, maximum tolerated dose −13.7% |

Each pair is one trial: the highest-dose arm (dark) and the comparator (light). Full results and arms are in the table above.

- In SURMOUNT-2, a 72-week phase 3 trial of 938 adults (18 or older) with BMI of 27 kg/m2 or higher and type 2 diabetes with HbA1c 7-10% (53-86 mmol/mol), in seven countries, body weight fell by 12.8% and 14.7% on the 10 mg and 15 mg arms, against 3.2% on placebo. [Source](https://doi.org/10.1016/s0140-6736(23)01200-x) · [Registry](https://clinicaltrials.gov/study/NCT04657003)

- In SURMOUNT-3, a 72-week phase 3 trial of 579 adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention, body weight changed by -18.4% on the Maximum tolerated dose (10 or 15 mg) arm, against 2.5% on placebo. [Source](https://doi.org/10.1038/s41591-023-02597-w) · [Registry](https://clinicaltrials.gov/study/NCT04657016)

- In SURMOUNT-4, an 88-week phase 3 trial of 670 adults with BMI of 30 or more, or 27 or more with a weight-related complication, excluding diabetes, body weight changed by -5.5% on the Continued tirzepatide, weeks 36 to 88 arm, against 14% on switched to placebo. [Source](https://doi.org/10.1001/jama.2023.24945) · [Registry](https://clinicaltrials.gov/study/NCT04660643)

- In SURMOUNT-5, a 72-week phase 3b trial of 751 adults with obesity but without type 2 diabetes, body weight fell by 20.2% on the Tirzepatide, maximum tolerated dose arm, against 13.7% on semaglutide, maximum tolerated dose. [Source](https://doi.org/10.1056/NEJMoa2416394) · [Registry](https://clinicaltrials.gov/study/NCT05822830)

## Regulatory status

**FDA Philippines**

- Registered only as the branded prescription medicine Mounjaro (12 certificates).

**US FDA**

- Approved for glycemic control in type 2 diabetes mellitus (Mounjaro); weight reduction in obesity or overweight with a comorbidity and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound). Drugs@FDA: Mounjaro (NDA215866, approved 13 May 2022); Zepbound (NDA217806, approved 8 November 2023). The approval covers the named branded medicine for its labelled use only, never a vial of the same substance sold for research use.

**European Medicines Agency**

- Approved for type 2 diabetes mellitus and weight management (Mounjaro). Mounjaro, EMEA/H/C/005620, authorised 15 September 2022. The authorisation covers the named medicine only.

**Next milestone**

- None sought: an approved medicine already exists.

Checked 23 September 2026. [Primary source](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866)

How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the [regulation hub](https://www.philippinespeptides.com/legal), and every compound's status side by side is on the [status page](https://www.philippinespeptides.com/legal/status). This is general information, not legal advice.

Tirzepatide is sold in the Philippines as a registered prescription medicine; dated prices are on the [Mounjaro price page](https://www.philippinespeptides.com/guides/mounjaro-philippines).

## Who should not use Tirzepatide

Do not use if

- Personal or family history of medullary thyroid carcinoma (MTC)

- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

- History of severe pancreatitis

- Type 1 diabetes

- Pregnancy or breastfeeding

- Severe gastrointestinal disease including gastroparesis

Everything above is research framing. For the material itself, our partner and supplier lists [tirzepatide 15mg at Primara Labs](https://www.primaralabs.com/marketplace/tirzepatide-15mg?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline) for ₱2,100 (₱1,890 with 10% off), from stock inside the Philippines.

## FAQ

### Has FDA Philippines warned about tirzepatide vials?

Yes. FDA Advisory No. 2026-1019, 4 September 2026: The FDA warned the public against buying or using the unregistered drug product Peptatide Tirzepatide 15mg sold with Peptatide bacteriostatic water, which has no Certificate of Product Registration. FDA Advisory No. 2026-1020, 4 September 2026: The FDA warned the public against buying or using an unregistered 30 mg multi-use tirzepatide vial sold with bacteriostatic water, which has no Certificate of Product Registration. FDA Advisory No. 2026-0814, 30 July 2026: The FDA warned the public against buying or using the unregistered drug product Tirz Laine Tirzepatide 30mg/3 mL 99% Purity, which has no Certificate of Product Registration. The regulation hub lists every advisory with its source.

### Is tirzepatide VAT-exempt in the Philippines?

FDA Advisory No. 2026-0065 added tirzepatide 2.5 mg to 15 mg per 0.6 mL solution for injection to the list of VAT-exempt health products for diabetes under the CREATE Act. The listing concerns the registered diabetes medicine; prescribing belongs with a licensed Philippine physician.

### Is Zepbound available in the Philippines?

A search of the FDA Verification Portal on 23 September 2026 returned no registered drug product for Zepbound. In the Philippines, tirzepatide is registered as Mounjaro, and Philippine pharmacies list Mounjaro rather than Zepbound.

### What is the difference between Mounjaro and a research-grade tirzepatide vial?

### How does tirzepatide differ from retatrutide?

### What evidence exists for tirzepatide?

The evidence level for tirzepatide is phase 3 human. Completed human randomised controlled trials counted: 5 (SURMOUNT obesity trials in the trials dataset; the wider literature, including diabetes trials, is larger). Studied for: Obesity and overweight, obesity with type 2 diabetes, maintenance of weight reduction, and comparison with semaglutide. Key source: Jastreboff AM et al. N Engl J Med 2022 (SURMOUNT-1).

## Where to get Tirzepatide in the Philippines

Our partner and supplier

Our partner and supplier Primara Labs lists tirzepatide 15mg at ₱2,100 a vial, or ₱1,890 with 10% off. Stock sits in Metro Manila, so Metro Manila addresses are same-day and the rest of the country is 1 to 5 business days.

Mounjaro is listed by the major Philippine drugstore chains against a prescription; no Philippine registration has been identified for Zepbound. The Tirzepatide Philippines 2026 guide covers pharmacy prices and availability, and the regulation hub covers the legal framework for peptides in the Philippines.

[Tirzepatide Philippines 2026 Guide](https://www.philippinespeptides.com/guides/tirzepatide-philippines-2026)[Supply index](https://www.philippinespeptides.com/supply)

## Primary sources

Citations supporting the clinical claims on this page. Each entry links to the primary record.

- 1. SURPASS-2 Trial: tirzepatide vs semaglutide Trial Frias JP et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." N Engl J Med 2021;385:503-515. [DOI: 10.1056/NEJMoa2107519](https://doi.org/10.1056/NEJMoa2107519)

- 2. SURMOUNT-1 Trial: tirzepatide for obesity Trial Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med 2022;387:205-216. [DOI: 10.1056/NEJMoa2206038](https://doi.org/10.1056/NEJMoa2206038)

- 3. SURMOUNT-4: weight maintenance Trial Aronne LJ et al. "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction." JAMA 2024;331(1):38-48. [DOI: 10.1001/jama.2023.24945](https://doi.org/10.1001/jama.2023.24945)

- 4. Mounjaro Prescribing Information: FDA Label Label Eli Lilly. Mounjaro (tirzepatide) injection prescribing information. US FDA-approved label. [Source](https://pi.lilly.com/us/mounjaro-uspi.pdf)

- 5. Dual GIP/GLP-1 receptor agonist mechanism Mechanism Coskun T et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept." Mol Metab 2018;18:3-14. [DOI: 10.1016/j.molmet.2018.09.009](https://doi.org/10.1016/j.molmet.2018.09.009)

How this was gathered

Findings, evidence levels and sources are from the Research Desk datasets published by [Primara Labs, our partner and supplier](https://www.primaralabs.com/research/evidence?utm_source=philippinespeptides&utm_medium=referral&utm_campaign=inline), synced 23 September 2026 and summarised here in this site’s own words.

Risk · Disclosure · Editorial Status

This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.

In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.

**Editorial Status**

- Non-clinical

**Affiliation**

- Not a clinic · Not a pharmacy

**Last Updated**

- September 24, 2026

### Related peptides

- [Compound Retatrutide](https://www.philippinespeptides.com/peptides/retatrutide)

- [Compound Semaglutide](https://www.philippinespeptides.com/peptides/semaglutide)

- [Compound Cagrilintide](https://www.philippinespeptides.com/peptides/cagrilintide)

- [Compound AOD-9604](https://www.philippinespeptides.com/peptides/aod9604)

### Related guides

- [Guide Tirzepatide Philippines 2026: Mounjaro & Zepbound Pricing, Sourcing & Legality 10 min read](https://www.philippinespeptides.com/guides/tirzepatide-philippines-2026)

- [Comparison Retatrutide vs Tirzepatide: Full Comparison 8 min read](https://www.philippinespeptides.com/guides/retatrutide-vs-tirzepatide)

- [Guide GLP-1 Peptides in the Philippines Everything about GLP-1 weight loss peptides in the Philippines. 5 min read](https://www.philippinespeptides.com/guides/glp1-philippines)

- [Guide Managing GLP-1 Side Effects Practical management protocol for GLP-1 side effects on Retatrutide, Tirzepatide, and Semaglutide. 4 min read](https://www.philippinespeptides.com/guides/glp1-side-effects)

---
Philippines Peptides sells nothing. Primara Labs is our partner and supplier. This is general information, not medical or legal advice.